Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Rights of an allogeneic, non-viral chimeric antigen receptor (CAR) technology platform. Non-viral chimeric antigen receptor (CAR) technology platform which leverages Cytokine-Induced Killer (C.I.K.) cells as immune effector cells, is developed at University of Milano-Bicocca.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Technology Systems
Primary Office
  • Piazza dell'Ateneo Nuovo, 1
  • 20126 Milan
  • Italy

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform‘s full profile, request access.

Request full access to PitchBook

Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Non-Viral Chimeric Antigen Receptor (CAR) Immunotherapy Platform‘s full profile, request access.

Request full access to PitchBook